Abstract:Triple negative (ER−/PR−/EGFR−) breast cancer accounts for 15% of all breast cancers. A large percentage of them are African and African-American women who are premenopausal. Histologically, the cancers are poorly differentiated, and most fall into the basal subgroup of breast cancers. Because of the absence of specific treatment guidelines, these patients are managed with standard treatment which leaves them associated with a high rate of local and systemic relapse. Angiogenesis is crucial for breast tumor growth and progression. Our laboratory has recently established that Tunicamycin (TM; an antibiotic and a glucosamine-containing pyrimidine nucleoside) interferes with the dynamic relationship between asparagine-linked (N-linked) glycosylation and angiogenesis. As a result, the xenograft developed in athymic nude mice [Balb/c (nu/nu)] with human breast cancer cell line MDA-MB-231 is reduced ∼65% in one week when Tunicamycin was given orally (0.25 mg/Kg) twice per week. To understand if it is due to a direct effect of Tunicamycin on the tumor microvsculature or a nutritional deprivation of the tumor cells due to insufficient blood flow, we have studied the effect of Tunicamycin on MDA-MB-231 breast cancer cells. When titrated with Tunicamycin (0.1 µg/ml, 1.0 µg/ml and 10.0 µg/ml) for seven days, the cell growth was inhibited almost quantitatively at all concentrations and as a function of time. In addition, no colony was formed at 1 µg/ml of Tunicamycin, the concentration used in all our experiments. Protein expression by western blotting and the gene expression by qRT-PCR indicated down-regulation of cyclin D1, and up-regulation of wild type p53, phopspho p53(ser 392), Bcl-2 and caspase-3 with no changes in the cdk-4 expression. These results strongly supported cell cycle arrest in G1 followed by the induction of apoptosis. Our recent study has demonstrated that Tunicamycin induces ER stress and consequently the apoptosis by unfolded protein response (upr) in breast tumor microvasculature. When examined, the MDA-MB-231 cells expressed high levels of GRP-78 as well as phospho PERK, a translational attenuator. Thus, we conclude that the MDA-MB-231 breast cancer cells experienced upr-mediated apoptotic death in the presence of Tunicamycin and strongly supported Tunicamycin9s potential for a glycotherapeutic for treating a triple negative breast cancer in the clinic. Supported in part by grants from Susan G. Komen for the Cure (BCTR06582) and NIH/NCRR/RCMI G12-RR03035 (KB). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2095. doi:10.1158/1538-7445.AM2011-2095

Tunicamycin Enhances the Antitumor Activity of Trastuzumab on Breast Cancer in Vitro and in Vivo

Concomitant Targeting Of Tumor Cells And Induction Of T-Cell Response Synergizes To Effectively Inhibit Trastuzumab-Resistant Breast Cancer

Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells in Vitro and in Vivo

Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer

Tunicamycin Potentiates Cisplatin Anticancer Efficacy Through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma.

Trastuzumab in Combination with PEGylated Interferon-Α1b Exerts Synergistic Antitumor Activity Through Enhanced Inhibition of HER2 Downstream Signaling and Antibody-Dependent Cellular Cytotoxicity.

Trastuzumab-Cisplatin Conjugates for Targeted Delivery of Cisplatin to Her2-Overexpressing Cancer Cells

Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis

Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity

Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway

Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer

Abstract 2095: Tunicamycin inhibits triple negative breast cancer progression

Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer

Combating HER2-overexpressing Breast Cancer Through Induction of Calreticulin Exposure by Tras-Permut CrossMab.

Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.

Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells

Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.

Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy

Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer

Trastuzumab Enhances the Anti-Tumor Effects of the Histone Deacetylase Inhibitor Sodium Butyrate on a HER2-overexpressing Breast Cancer Cell Line